文献速递头颈外科

头颈癌淋巴结外侵犯的风险分层——对治疗强化的意义

Risk Stratification for Extranodal Extension in Head and Neck Cancers-Implication for Treatment Intensification.
PubMed 文献 · Head Neck · 2025-03-28

这项回顾性单中心研究纳入最终组织学提示淋巴结外侵犯(ENE)的初治头颈癌患者,评估ENE范围的最佳截断值及其与临床病理因素的交互作用。病理学ENE见于122例患者(12.4%)。以2 mm截断值区分Mi-ENE与Ma-ENE时,总体生存(OS)和无病生存(DFS)在未匹配及倾向评分匹配队列中均无显著差异;ROC分析显示ENE范围4 mm截断值的曲线下面积最高(AUC 0.52),且该4 mm截断值可预测辅助放化疗的治疗获益(HR 0.27,95%CI 0.1-0.73)。

要点

  • 病理学ENE见于122例患者(12.4%)。
  • 2 mm截断值区分Mi-ENE与Ma-ENE时,未匹配队列OS 40.9% vs 33.6%(p=0.7)、DFS 34.05% vs 26.12%(p=0.5),倾向评分匹配队列OS HR 1.08(p=0.82)、DFS HR 0.95(p=0.89),均无显著差异。
  • ROC分析显示ENE范围4 mm截断值的AUC最高(0.52),且该截断值可预测辅助CRT的治疗获益(HR 0.27,95%CI 0.1-0.73)。

核心结论

  • ENE范围的标准2 mm截断值未能对OS/DFS提供足够风险区分。
  • ROC分析确定的4 mm截断值对DFS具有最佳预测能力。

研究设计与样本

  • 回顾性单中心研究,纳入最终组织学提示ENE的初治头颈癌患者。
  • 病理学ENE见于122例患者(12.4%)。

主要发现

  • 以2 mm截断值区分Mi-ENE与Ma-ENE,未匹配队列OS 40.9% vs 33.6%(p=0.7)、DFS 34.05% vs 26.12%(p=0.5),无显著差异。
  • 倾向评分匹配队列中,2 mm截断值区分Mi-ENE与Ma-ENE的OS HR 1.08(p=0.82)、DFS HR 0.95(p=0.89),无显著差异。
  • ROC分析显示ENE范围4 mm截断值的AUC最高(0.52)。
  • 辅助CRT对Ma-ENE的OS(HR 0.42,95%CI 0.18-0.9)和DFS(HR 0.33,95%CI 0.15-0.70)获益有统计学意义,Mi-ENE未见此获益。
  • 修订的4 mm截断值可预测辅助CRT的治疗获益(HR 0.27,95%CI 0.1-0.73)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extranodal extension (ENE) is an important adverse prognostic indicator for head and neck cancers. However, ENE needs further risk stratification in terms of optimum cutoff for the extent of ENE and interaction with clinicopathological risk factors. METHODS: Retrospective single-center study on patients with treatment-naïve head and neck cancer with final histology indicating ENE. RESULTS: Pathological ENE was observed in 122 patients (12.4%). With the 2 mm cutoff separating Mi-ENE and Ma-ENE, no difference was observed in overall survival (OS) and disease-free survival (DFS) for unmatched (OS: 40.9% vs. 33.6%, p = 0.7; DFS: 34.05% vs. 26.12%, p = 0.5) as well as propensity score-matched cohort (OS: HR 1.08, p = 0.82; DFS: HR 0.95, p = 0.89). Receiver-operator curve (ROC) analysis showed the highest area under the curve with a 4 mm cutoff for the extent of ENE (AUC: 0.52). On assessing the impact of adjuvant chemoradiation (CRT) on Ma-ENE and Mi-ENE, only Ma-ENE showed OS (HR: 0.42, 95% CI: 0.18-0.9) and DFS (HR: 0.33, 95% CI: 0.15-0.70) benefit with CRT, which was statistically significant. The revised 4 mm cutoff was predictive of therapeutic benefit with adjuvant CRT (HR: 0.27, 95% CI: 0.1-0.73). Clinicopathological factors with statistically significant interaction with ENE in worsening OS and DFS were tumor location in tongue/floor of mouth (OS), T3/T4 category (OS), depth of invasion greater than 10 mm (OS), ≥ 5 nodes with metastasis (OS), and male sex (DFS). CONCLUSION: The standard 2 mm cutoff for the extent of ENE failed to reveal sufficient hazard discrimination for OS/DFS. Instead, the 4 mm cutoff determined on ROC analysis was found to have the best predictive ability for DFS.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Panda S, Kumar R, Kakkar A, et al. Risk Stratification for Extranodal Extension in Head and Neck Cancers-Implication for Treatment Intensification. Head Neck. 2025. PMID: 40151024. doi:10.1002/hed.28144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。